Hologic has received CE mark for the new Panther Fusion system and its assays developed for flu and respiratory testing.
The Panther Fusion system is designed as an in-lab upgrade to improve the testing capabilities by adding flexibility of polymerase chain reaction (PCR) to current Panther system’s transcription-mediated amplification (TMA).
The availability of multiple chemistries on a single platform is expected to deliver comprehensive lab testing portfolio.
The new system features sample-to-result automation, the possibility for multiple tests from a single sample, random access sample processing, STAT capabilities, and continuous loading.
Panther Fusion further includes comparatively higher throughput of around 335 Panther Fusion tests or approximately 500 Fusion and Aptima tests in eight hours.
The open access functionality of the system provides flexibility for laboratory-developed tests and protocols, while the automation of workflow decreases overall hands-on-time.
Hologic EMEA Sales Diagnostics vice-president João Malagueira said: "The Panther Fusion system, the latest innovation from our Diagnostics division, creates an integrated workflow that provides our customers with enhanced flexibility and increased efficiency.
"The addition of the flu and respiratory assays to the broad menu of Aptima tests already available for the Panther instrument further extends the range of diagnostics tests that laboratories can run on one Hologic system.”
Panther Fusion Flu A/B/RSV, Panther Fusion Paraflu, and Panther Fusion AdV/hMPV/RV tests are included in the Panther Fusion respiratory panel of assays.
The assays allow both standalone and combined operation from a single patient sample.
The combination of these assays with the Aptima TMA assays provides an assortment of TMA, real-time TMA and real-time PCR with complete sample-to-result automation on the Panther Fusion system.